Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
about
The role of the ALK receptor in cancer biologyNovel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.Overview and recent advances in the treatment of neuroblastoma.Crizotinib synergizes with cisplatin in preclinical models of ovarian cancer.Detection of tumor ALK status in neuroblastoma patients using peripheral blood.ALK alteration is a frequent event in aggressive breast cancers.Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma.Relapsed neuroblastomas show frequent RAS-MAPK pathway mutationsMetformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway.Neuroblastoma treatment in the post-genomic era.Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphomaNovel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells.Advances in emerging drugs for the treatment of neuroblastoma.The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers.A genome-wide microRNA profiling indicates miR-424-5p and miR-503-5p as regulators of ALK expression in neuroblastoma.CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma.High expression of β-catenin contributes to the crizotinib resistant phenotype in the stem-like cell population in neuroblastoma.Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers.The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.Cell death-based treatment of neuroblastoma.p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy.Targeting Autophagy in ALK-Associated Cancers.ALK in Neuroblastoma: Biological and Therapeutic Implications.Effects of DDIT4 in Methamphetamine-Induced Autophagy and Apoptosis in Dopaminergic Neurons.A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy.
P2860
Q26738384-DFC9DA17-631E-4667-B4DA-1A0D0B525145Q27853323-9AC5DA28-A09A-4CFE-8C61-5111A946D7B0Q27853330-15637057-AE93-4EFE-8285-A8E49223EE5CQ30238693-C2D6217F-303E-4B42-88EC-13BA175082E1Q33623108-E2C58BAD-EFD8-4EEB-9B2D-2F4A4D53EDC4Q35469393-59048269-76D4-4E97-B98F-CE88D927B1C8Q36105958-7F3C70CC-CC21-4E6B-9FA7-FB7C13F9873EQ36562108-C66CF078-41CD-41FC-AC6E-DEF50ADEAE87Q36641925-584947A9-5020-4549-8C24-F13004777B3AQ37376294-0DA8E5DF-2DD9-4507-9FD7-DEEA25E84C6AQ37633731-3E1F4C1A-4853-4BFD-9147-6EC4D2A0A271Q37687313-193F0246-D612-4C92-9A08-8F8C9A22AC92Q37701501-DCF7994F-BE8C-4C57-99B7-4C23638F7137Q38806238-97985B62-A7A1-41CE-8637-9E7330EE48B3Q39158415-2E367C0A-0EAD-4318-933C-B01A0F951DC6Q41116766-67F02B39-81CA-48BB-AAC7-DF240097F4BDQ41346041-AF601B32-6AD7-4A2B-9719-F8C5749C49B6Q46167320-7F9AB8D5-B114-4BDF-B719-94581D81203BQ46874296-9E4C8AF4-C859-4432-B833-BD8289861BF3Q47107337-E14CF955-EDC5-4CE8-AF37-617A1C0BB605Q47134648-EA5FD88C-0253-47FD-A41A-39F4DFF129A7Q47590630-7DCD38E4-295D-48E9-AAA8-F50AE151F223Q47839039-74350D07-AC19-463F-81E5-B2FFDC5D9BE7Q48689521-136ADB16-948C-4ACC-8A22-1096E6F8A776Q49545616-E8F2AB40-AFC8-461C-B21A-6B745A14484BQ52324760-2DE68157-2107-4EAE-A2F6-F18621DD558CQ53175834-FD50D80B-76A2-454C-924B-13BBCB09B92DQ54110132-90BDE128-8DE5-4253-B151-9F683397CBC7
P2860
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Molecular rationale for the us ...... in ALK-mutated neuroblastoma.
@en
type
label
Molecular rationale for the us ...... in ALK-mutated neuroblastoma.
@en
prefLabel
Molecular rationale for the us ...... in ALK-mutated neuroblastoma.
@en
P2093
P2860
P50
P356
P1433
P1476
Molecular rationale for the us ...... in ALK-mutated neuroblastoma.
@en
P2093
Amanda L Christie
Anna M Azarova
Kenneth N Ross
Lauren E Drake
Namrata Bhatnagar
Nathan F Moore
Nathanael S Gray
Qinsong S Liu
Rani E George
Stacey Frumm
P2860
P304
P356
10.18632/ONCOTARGET.2372
P407
P577
2014-09-01T00:00:00Z